Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Recent Advances in Long-Acting Drug Delivery and Formulations"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 6038
Special Issue Editors
Interests: preformulation studies; cyclodextrins; solubility enhancement; modified release systems; niosomes; ocular delivery; irritation models
Interests: drug delivery; cancer; pancreatic diseases; bioprinting; biosensor; nanotechnology
Special Issue Information
Immediate-release delivery systems have been critiqued for not being able to consistently provide optimum therapy for chronic disease conditions, as well as for their potential to induce adverse effects. This is mainly due to the typical rapid, pulse-release and absorption patterns of their drug cargo, leading to rapidly fluctuating systemic drug concentration.
Long-acting drug delivery systems (LADDSs) encompass a range of formulations and technologies for precisely delivering drug molecules into target tissues either through the systemic circulation or via localized organs/tissues (e.g., skin, eye and specific lesions) for treating chronic diseases such as diabetes, cancer and brain disorders, as well as for treating age-related eye diseases. LADDSs have been shown to prolong drug release from several hours up to 3 years, depending on characteristics of the drug, disease and delivery system. LADDSs can offer potentially safer, more effective and patient-friendly treatment options compared to more invasive modes of drug administration such as repeated injections or minor surgical intervention. LADDSs include oral sustained release systems, injectable implants, in situ forming implants, inserts, wafers, transdermal patches, microspheres and nanoparticles.
Simple and scalable LADDS fabrication techniques such as the solvent casting method, other innovative delivery systems such as microneedle fabrication, and technologies such as electrospinning and 3D printing can yield personalized implantable devices.
The new knowledge obtained from novel research ideas and manuscripts will contribute to improving bioavailability, reducing unwanted side effects, achieving drug targeting or promoting better patient treatment adherence.
We would be much appreciative if you would consider being one of our authors contributing to this Special Issue. All types of submissions are welcome, including original research articles, and comprehensive reviews, etc.
Dr. Hamdy Abdelkader
Dr. Adel Al-Fatease
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- in situ forming implants
- 3D printing
- retinal diseases
- glaucoma brain disorders